Nörotransmitter Metabolizma Bozuklukları
Özet
Nörotransmitter metabolizma bozuklukları; monoamin ve aminoasit nörotransmitterlerin üretim, depolanma, transfer veya yıkım süreçlerindeki kalıtımsal defektlerden kaynaklanan nadir ancak klinik yönetimi kritik hastalıklardır. Serebral palsi ve erken başlangıçlı Parkinson gibi daha yaygın nörolojik durumlarla benzerlik gösterdikleri için tanı süreçleri sıklıkla gecikmektedir. Erken teşhis, doğru genetik tarama ve metabolik destek tedavileri (BH4, L-Dopa vb.), hastaların nörolojik fonksiyonlarını korumak ve prognozu iyileştirmek adına hayati öneme sahiptir. Klinik yaklaşımda detaylı anamnez, BOS incelemeleri ve dışlayıcı tanı yöntemleri, hastayı doğru tedavi algoritmasına yönlendirmek için temel şarttır.
Neurotransmitter metabolism disorders arise from inherited defects in the synthesis, storage, transport, or degradation of monoamine and amino acid neurotransmitters, presenting a critical clinical challenge. These conditions often face diagnostic delays because they mimic more common neurological disorders like cerebral palsy and early-onset Parkinson's disease. Early diagnosis through rigorous clinical assessment, cerebrospinal fluid analysis, and targeted genetic screening is essential for effective management. Timely implementation of specific metabolic therapies, such as BH4 and L-Dopa, remains the standard for preserving neurological function and improving patient outcomes.
Referanslar
Nestler EJ, Hyman SE, Holtzman DM, Malenka RC. Synaptictransmission. Molecular Neuropharmacology. Third ed. McGrawHill;2014
Brennenstuhl H, Jung-Klawitter S, Assmann B, Opladen T. InheritedDisorders of Neurotransmitters: Classification and Practical Approaches for Diagnosis and Treatment. Neuropediatrics. 2019 Feb;50(1):2-14. doi: 10.1055/s-0038-1673630. Epub 2018 Oct 29. PMID: 30372766.
Fernandez-Alvarez E (2009) Movementdisorders in children: recentadvances in management. Indian J Pediatr 76:531–536
Crane BR, Arvai AS, Ghosh DK, et al. Structure of nitricoxidesynthaseoxygenasedimer with pterinandsubstrate. Science1998;279(5359):2121–2126
Thöny B, Blau N. Mutations in the BH4-metabolizing genesGTP cyclohydrolase I, 6-pyruvoyl-tetrahydropterin synthase, sepiapterinreductase, carbinolamine-4a-dehydratase, anddihydropteridinereductase. Hum Mutat 2006;27:870-7.
Opladen T, Hoffmann G, Hörster F, et al. Clinical and biochemical characterization of patients with early infantileonset of autosomalrecessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia. MovDisord 2011;26(01):157–161
Niederwieser A, Shintaku H, Leimbacher W, et al. “Peripheral” tetrahydrobiopterin deficiency with hyperphenylalaninaemiaduetoin complete 6-pyruvoyl tetrahydropterinsynthase deficiency or heterozygosity. Eur J Pediatr 1987;146(03):228–232
Leuzzi V, Carducci CA, Carducci CL, et al. Phenotypicvariability, neurologicaloutcomeandgeneticsbackground of 6-pyruvoyltetrahydropterin synthasedeficiency. ClinGenet 2010;77(03):249–257
Opladen T, Hoffman G, Blau N. An internationalsurveyof patients with tetrahydrobiopterindeficiencies presenting with hyperphenylalaninaemia. JIMD 2012;35(6):963-73
Thöny B, Neuheiser F, Kierat L, et al. Mutations in the pterin-4alpha-carbinolamine dehydratase (PCBD) gene cause a benignform of hyperphenylalaninemia. Hum Genet 1998;103(02):162–167
Blau N, Thöny B, Cotton RGH, et al. Disorders of tetrahydrobiopterinandrelatedbiogenicamines. In: Scriver CR, Beaudet AL, SlyWS et al., ed. TheMetabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001:1725–1776
Hyland K, Shoffner J, Heales SJ. Cerebralfolatedeficiency. J InheritMetabDis 2010;33(05):563–570
Longo N. Disorders of biopterinmetabolism. J InheritMetabDis 2009;32:333-42
Nygaard TG. Dopa-responsivedystonia. Delineation of theclinical syndrome and cluestopathogenesis.AdvNeurol 1993;60:577–585
Allen GF, Land JM, Heales SJ. A newperspective on thetreatment of aromatic L-amino aciddecarboxylasedeficiency. MolGenetMetab2009;97(1):6-14.
Kurian MA, Gissen P, Smith M, Heales SJR, Clayton PT. Themonoamineneurotransmitterdisorders: an expandingrangeof neurologicalsyndromes. TheLancetNeurology2011;10(8):721-733
Segawa M, Nomura Y, Nishiyama N. Autosomal dominant guanosinetriphosphatecyclohydrolase I defi ciency (Segawadisease). AnnNeurol2003;54(Suppl 6):S32-45.
Tadic V, Kasten M, Brüggemann N, Stiller S, Hagenah J, Klein C. Dopa-responsivedystoniarevisited: diagnosticdelay, residualsigns, andnonmotorsigns. ArchNeurol 2012;69(12):1558–1562
Friedman J, Roze E, Abdenur JE, et al. Sepiapterinreductasedeficiency: a treatablemimic of cerebralpalsy. AnnNeurol 2012; 71(04):520–530
Friedman J, Hyland K, BlauN, MacCollin M. Dopa-responsive hypersomniaandmixed movement disorder due to sepiapterinreductase deficiency. Neurology 2006;67(11):2032–2035
Neville BG, Parascandalo R, Farrugia R, Felice A. Sepiapterinreductasedeficiency: a congenitaldopa-responsive motor andcognitivedisorder. Brain 2005;128(Pt 10):2291–2296
Carducci C, Santagata S, Friedman J, et al. Urinesepiapterinexcretion as a newdiagnostic marker forsepiapterinreductasedeficiency. MolGenetMetab 2015;115(04):157–160
Willemsen MA, Verbeek MM, Kamsteeg EJ, et al. Tyrosinehydroxylasedeficiency: a treatabledisorder of braincatecholaminebiosynthesis. Brain 2010;133(Pt 6):1810–1822
Pons R, Syrengelas D, Youroukos S, et al. Levodopa-induceddyskinesias in tyrosinehydroxylasedeficiency. MovDisord2013;28(08):1058–1063
Brun L, Ngu LH, Keng WT, et al. Clinicalandbiochemicalfeaturesof aromatic L-amino aciddecarboxylasedeficiency. Neurology2010;75: 64–71.
Hyland K, Surtees RA, RodeckC, Clayton PT. Aromatic L-amino aciddecarboxylasedeficiency: clinicalfeatures, diagnosis, andtreatment of a newinbornerror of neurotransmitteraminesynthesis. Neurology 1992;42(10):1980–1988
Cheung NW, Earl J. Monoamineoxidasedeficiency: a cause of flushingandattention-deficit/hyperactivitydisorder? ArchInternMed 2001;161(20):2503–2504
Whibley A, Urquhart J, Dore J, et al. Deletion of MAOA and MAOB in a malepatientcauses severe developmentaldelay, intermittenthypotoniaandstereotypicalhandmovements. Eur J Hum
Genet 2010;18(10):1095–1099
Gillman. P. K. Advancespertainingtothepharmacologyandinteractions of irreversible nonselective monoamineoxidaseinhibitors. J ClinPsychopharmacol2011;31:66-74.
Robertson D, Garland EM. Dopamine beta-hydroxylasedeficiency. In: Adam MP, Ardinger HH, Pagon RA, et al.,eds. GeneReviews® [Internet]. Seattle, WA: University of Washington; 1993-2018. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1474/. AccessedOctober 1, 2018
Kurian MA, Zhen J, Cheng SY et al. Homozygousloss-offunctionmutations in the gene encoding the dopamine transporter are associated within fantileparkinsonism-dystonia. J ClinInvest2009;119(6):1595-603
Ng J, Zhen J, Meyer E, et al. Dopaminetransporterdeficiencysyndrome: phenotypicspectrumfrominfancy to adulthood. Brain 2014;137(Pt 4):1107–1119
Yildiz Y, Pektas E, Tokatli A, Haliloglu G. Hereditarydopaminetransporterdeficiencysyndrome: challenges in diagnosisandtreatment. Neuropediatrics 2017;48(01):49–52
Rilstone JJ, Alkhater RA, Minassian BA. Brain dopamine-serotoninvesicular transport diseaseanditstreatment. N Engl J Med2013;368(06):543–550
Ng J, Heales SJ, Kurian MA. Clinicalfeaturesandpharmacotherapy of childhood monoamineneurotransmitter disorders. PaediatrDrugs 2014;16(04):275–291
Kuster, Alice, et al. "Diagnostic approach to neurotransmitter monoamine disorders: experience from clinical, biochemical, and genetic profiles." Journal of inherited metabolic disease 41.1 (2018): 129-139.
Siu, Wai-Kwan. "Genetics of monoamine neurotransmitter disorders." Translational pediatrics 4.2 (2015): 175.
Jakobs C, BojaschM, Mönch E, Rating D, Siemes H, Hanefeld F (1981) Urinary excretion of gamma-hydroxybutyric acid in a patient with neurological abnormalities. The probability of a new inborn error of metabolism. Clin Chim Acta 111:169–178
Pearl PL, Gibson KM, Acosta MT et al (2003) Clinical spectrum of succinic semialdehyde dehydrogenase deficiency. Neurology 60:1413–1417
Pearl PL, Shukla L, Theodore WH, Jakobs C, Gibson KM (2011) Epilepsy in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism. Brain and Development 33:796–805
Vogel KR, Ainslie GR, Gibson KM (2016) mTOR inhibitors rescue prematüre lethality and attenuate dysregulation of GABAergic/ glutamatergic transcription in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism. J Inherit Metab Dis 39:877–886
Lakhani R, Vogel KR, Till A et al (2014) Defects in GABA metabolism affect selective autophagy pathways and are alleviated by mTOR inhibition. EMBO Mol Med 6:551–566
Applegarth DA, Toone JR (2004)Workshop report. Glycine encephalopathy(nonketotic hyperglycinemia): review and update. J Inherit Metab Dis 27:417–422
Hennermann JB, Berger JM, Grieben U, Scharer G, van Hove JLK(2012) Prediction of long-term outcome in glycine encephalopathy:a clinical survey. J Inherit Metab Dis 35:253–261
AlfadhelM, NashabatM, Al Qahtani H et al (2016) Mutation in SLC6A9 encoding a glycine transporter causes a novel form of non-ketotic hyperglycinemia in humans. Hum Genet 135:1263–1268
Baker PR, FriederichMW, SwansonMA et al (2014) Variant non-ketotic hyperglycinemia is caused by mutations in LIAS, BOLA3 and the novel gene GLRX2. Brain 137:366–379
Hoover-Fong JE, Shah S, van Hove JLK, Applegarth D, Toone J, Hamosh A (2004) Natural history of nonketotic hyperglycinemia in 65 patients. Neurology 63:1847–1853
Bjoraker KJ, Swanson MA, Coughlin CR 2nd et al (2016) Neurodevelopmental outcome and treatment efficacy of benzoate and dextromethorphan in siblings with attenuated nonketotic hyperglycinemia. J Pediatr 17:234–239
De Koning TJ (2017) Amino acid synthesis deficiencies. J Inherit Metab Dis 40:609–620
Tabatabaie L, Klomp LW, Berger R, de Koning TJ (2010) L-Serine synthesis in the central nervous system: a review on serine deficiency disorders. Mol Genet Metab 99:256–262
De Koning TJ, Klomp LW, van Oppen AC, Beemer FA, Dorland L, van den Berg I, Berger R (2004) Prenatal and early postnatal treatment in 3-phosphoglycerate-dehydrogenase deficiency. Lancet 364:2221–2222
